Indian diabetes market to reach US$ 1.4 bn by 2015, predicts IMARC

With around 51 Million diabetes patients, India promises to be amongst the most lucrative diabetes markets in the world. In 2009, the total sales of Insulin and Non-Insulin Anti-diabetics reached US$ 424 Million. Although, this represents just a fraction of the global sales, IMARC expects this market to surge in the future.

In 2009, Non-Insulin Anti-diabetics occupied 72% of the total diabetes market. Biguanides represented the leading drug class with a 43% market share. In the next five years, IMARC expects newer classes such as DPP-IV Inhibitors and GLP-1 Agonists to drive the Non-Insulin Anti-diabetics market. From a market share of 6% in 2009, IMARC expects DPP-IV Inhibitors to occupy 17% of the total Non-Insulin Anti-diabetics market by 2015.

Unlike Non-Insulin’s, the Insulin market in India was concentrated with the top five players occupying 96% of the total market. The Insulin market is expected to grow at a CAGR of 25% between 2010 and 2015, registering sales worth US$448 Million. During the next five years, the main drivers of this market will be the growth in the total drug treated population coupled with a much improved access and administration of Insulin.

Report Highlights

•A growing drug treated population coupled with the launch of several new drugs will drive the Indian diabetes market to US$1.4 Billion by 2015.
•In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 306 Million. This represented a highly fragmented market with USV being the leading player with a 14% share.
•USV’s Glycomet GP (Glimepiride+Metformin) was the leading drug in the Non-Insulin Anti-diabetics market with sales worth nearly US$ 10.5 Million
•IMARC expects around 15 new Drugs to be launched in the Non-Insulin Anti-diabetics market in the next five years. Seven of them are expected to be in the DPP-IV Inhibitor and GLP-1 Agonist classes.
•The Insulin Market was worth US$ 117 Million in 2009. Abbott was India’s biggest player accounting for 61% of the total sales.
•Sanofi Aventi’s Lantus (Insulin Glargine) represented one of the fastest growing drugs in the last five year and registered sales worth nearly 11 Million in 2009
•The total number of diabetes patients in India is expected to reach 87 Million by 2030. Around 56% of these patients will be from urban regions.

Forecasts: The report provides forecasts on:
•Number of diabetes patients
•Diagnosis and treatment rates in India
•Diabetes market
•Non-Insulin Anti-diabetics market
•Glitazones
•Biguanides
•Sulphonylureas
•Alpha-Glycosidase Inhibitors
•DPP-IV Inhibhitors
•GLP-1 Agonists
•Glinides
•All other Non-Insulin Anti-diabetic classes
•Insulin market

Competitive Landscape: This section covers:
•2005-2009 sales and market shares of top players in the diabetes market
•2005-2009 sales and market shares of top players in the Non-Insulin Anti-diabetics market
•2005-2009 sales and market shares of top players in various Non-Insulin drug classes
•2005-2009 sales of top drugs comprising the portfolio of key players in various Non-Insulin drug classes
•2005-2009 sales and market shares of top players in the Insulin market
•2005-2009 sales of top drugs comprising the portfolio of key players in the Insulin market.

Key Questions Answered in this report
•What is the total size of the diabetes population in India and what are it’s characteristics?
•What are the diagnosis and drug treatment rates for diabetes in India?
•What are the key factors driving the growth of diabetes medication in India?
•What is the size and breakup of the total diabetes market in India?
•What is the size and breakup of the total Non-Insulin diabetes market in India?
•What is the size and breakup of the total Insulin market in India?
•Who are the key players in the Indian diabetes market and how have they performed?
•What is the outlook of the Indian diabetes market in the next five years?
•Which new products are expected to be launched in the next five years?
•Which therapy classes will show the highest growth in the next five years?
•What are the road blocks in the Indian diabetes market?

To get the full version of the "Indian diabetes market report and outlook for 2010-2015" please get in touch with us by emailing us at sales@imarcgroup.com or you can call us on +91-11-43095788

About IMARC

For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

IMARC Group Delhi
press@imarcgroup.com

This release was published on openPR.